PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH

Gelijkaardige items

• PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
  door: Lu, P, et al.
  Gepubliceerd in: (2013)
• Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial
  door: Opoka-Winiarska, Violetta, et al.
  Gepubliceerd in: (2018)
• PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
  door: De Benedetti, F, et al.
  Gepubliceerd in: (2013)
• PReS13-SPK-1576: Unmeet needs in JIA treatment
  door: Ruperto, N
  Gepubliceerd in: (2013)
• Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
  door: De Benedetti, Fabrizio, et al.
  Gepubliceerd in: (2012)